Rimegepant: Effective Migraine Relief for Triptan-Unsuitable Adults

Research Summary

A new study published in Cephalalgia explores the effectiveness of rimegepant for individuals with migraines who cannot use triptans. In this phase 4 trial, 585 participants, primarily women with a mean age of 42.9 years, received either a 75-mg dose of rimegepant or a placebo. The study showed that rimegepant provided significant migraine pain relief at 2 hours post-dose, with 55.9% of patients experiencing relief compared to 32.7% with placebo. Moreover, rimegepant was effective across all secondary endpoints, including pain freedom and functional improvement. Importantly, it was well tolerated with no severe adverse effects, highlighting its potential as an alternative treatment for those unsuitable for triptans.

Study Details

📄 Title: Rimegepant for acute treatment of migraine in triptan-unsuitable adults: A randomized, double-blind, placebo-controlled phase 4 trial.

👥 Research Team: Ashina M et al.

📚 Published In: Cephalalgia

📅 Publication Date: 2025 Nov

⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.